Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories

Background Detection of the pathological and disease-associated alpha-synuclein (αSyn D ) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSyn D can be detected in the olfactory mucosa (OM) of MSA a...

Full description

Saved in:
Bibliographic Details
Published inMolecular neurodegeneration Vol. 16; no. 1; pp. 82 - 19
Main Authors Bargar, Connor, De Luca, Chiara Maria Giulia, Devigili, Grazia, Elia, Antonio Emanuele, Cilia, Roberto, Portaleone, Sara Maria, Wang, Wen, Tramacere, Irene, Bistaffa, Edoardo, Cazzaniga, Federico Angelo, Felisati, Giovanni, Legname, Giuseppe, Di Fonzo, Alessio, Xu, Rong, Gunzler, Steven Alexander, Giaccone, Giorgio, Eleopra, Roberto, Chen, Shu Guang, Moda, Fabio
Format Journal Article
LanguageEnglish
Published London BioMed Central 11.12.2021
BioMed Central Ltd
BMC
Subjects
Online AccessGet full text
ISSN1750-1326
1750-1326
DOI10.1186/s13024-021-00491-y

Cover

Abstract Background Detection of the pathological and disease-associated alpha-synuclein (αSyn D ) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSyn D can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. Methods OM samples were prospectively collected from patients with a probable diagnosis of MSA-P ( n  = 20, mean disease duration 4.4 years), MSA-C ( n  = 10, mean disease duration 4 years), PD ( n  = 13, mean disease duration 8 years), and healthy control subjects (HS) ( n  = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. Results The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83–1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Conclusions Our study provides evidence that OM-αSyn D may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.
AbstractList Background Detection of the pathological and disease-associated alpha-synuclein ([alpha]Syn.sup.D) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that [alpha]Syn.sup.D can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on [alpha]-synuclein Real-Time Quaking-Induced Conversion ([alpha]Syn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. Methods OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by [alpha]Syn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized [alpha]Syn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. Results The [alpha]Syn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, [alpha]Syn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce [alpha]Syn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the [alpha]Syn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Conclusions Our study provides evidence that OM-[alpha]Syn.sup.D may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, [alpha]Syn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials. Keywords: Alpha-synuclein, Olfactory mucosa, Real-Time Quaking-Induced Conversion, Misfolding, Biomarkers
Detection of the pathological and disease-associated alpha-synuclein ([alpha]Syn.sup.D) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that [alpha]Syn.sup.D can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on [alpha]-synuclein Real-Time Quaking-Induced Conversion ([alpha]Syn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by [alpha]Syn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized [alpha]Syn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. The [alpha]Syn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, [alpha]Syn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce [alpha]Syn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the [alpha]Syn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Our study provides evidence that OM-[alpha]Syn.sup.D may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, [alpha]Syn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.
Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that αSynD can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes.BACKGROUNDDetection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that αSynD can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes.OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data.METHODSOM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data.The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability.RESULTSThe αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability.Our study provides evidence that OM-αSynD may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.CONCLUSIONSOur study provides evidence that OM-αSynD may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.
Background Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSynD can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. Methods OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. Results The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83–1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Conclusions Our study provides evidence that OM-αSynD may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.
Detection of the pathological and disease-associated alpha-synuclein (αSyn ) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson's disease (PD). We recently showed that αSyn can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83-1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Our study provides evidence that OM-αSyn may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.
Background Detection of the pathological and disease-associated alpha-synuclein (αSyn D ) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSyn D can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. Methods OM samples were prospectively collected from patients with a probable diagnosis of MSA-P ( n  = 20, mean disease duration 4.4 years), MSA-C ( n  = 10, mean disease duration 4 years), PD ( n  = 13, mean disease duration 8 years), and healthy control subjects (HS) ( n  = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. Results The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83–1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Conclusions Our study provides evidence that OM-αSyn D may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.
Abstract Background Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system atrophy (MSA) and Parkinson’s disease (PD). We recently showed that αSynD can be detected in the olfactory mucosa (OM) of MSA and PD patients. For this reason, we have performed the first interlaboratory study based on α-synuclein Real-Time Quaking-Induced Conversion (αSyn_RT-QuIC) analysis of OM samples collected from PD and MSA patients with the parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. Methods OM samples were prospectively collected from patients with a probable diagnosis of MSA-P (n = 20, mean disease duration 4.4 years), MSA-C (n = 10, mean disease duration 4 years), PD (n = 13, mean disease duration 8 years), and healthy control subjects (HS) (n = 11). Each sample was analyzed by αSyn_RT-QuIC in two independent specialized laboratories, one located in Italy (ITA-lab) and one located in the USA (USA-lab). Both laboratories have developed and used harmonized αSyn_RT-QuIC analytical procedures. Results were correlated with demographic and clinical data. Results The αSyn_RT-QuIC analysis reached a 96% interrater agreement of results (IAR) between laboratories (Kappa = 0.93, 95% CI 0.83–1.00). In particular, αSyn_RT-QuIC seeding activity was found in the OM of 9/13 patients with PD (sensitivity 69%, IAR 100%) and 18/20 patients with MSA-P (sensitivity 90%, IAR 100%). Interestingly, samples collected from patients with MSA-C did not induce αSyn_RT-QuIC seeding activity, except for one subject in USA-lab. Therefore, we found that MSA-P and MSA-C induced opposite effects. Regardless of disease diagnosis, the αSyn_RT-QuIC seeding activity correlated with some clinical parameters, including the rigidity and postural instability. Conclusions Our study provides evidence that OM-αSynD may serve as a novel biomarker for accurate clinical diagnoses of PD, MSA-P, and MSA-C. Moreover, αSyn_RT-QuIC represents a reliable assay that can distinguish patients with MSA-P from those with MSA-C, and may lead to significant advancements in patients stratification and selection for emerging pharmacological treatments and clinical trials.
ArticleNumber 82
Audience Academic
Author Di Fonzo, Alessio
Legname, Giuseppe
Cazzaniga, Federico Angelo
Tramacere, Irene
Bistaffa, Edoardo
Giaccone, Giorgio
Wang, Wen
Felisati, Giovanni
Chen, Shu Guang
Portaleone, Sara Maria
Gunzler, Steven Alexander
De Luca, Chiara Maria Giulia
Bargar, Connor
Devigili, Grazia
Eleopra, Roberto
Elia, Antonio Emanuele
Xu, Rong
Cilia, Roberto
Moda, Fabio
Author_xml – sequence: 1
  givenname: Connor
  surname: Bargar
  fullname: Bargar, Connor
  organization: Department of Pathology, Case Western Reserve University School of Medicine
– sequence: 2
  givenname: Chiara Maria Giulia
  surname: De Luca
  fullname: De Luca, Chiara Maria Giulia
  organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA)
– sequence: 3
  givenname: Grazia
  surname: Devigili
  fullname: Devigili, Grazia
  organization: Unit of Neurology 1 - Parkinson and Movement Disorders, Fondazione IRCCS Istituto Neurologico Carlo Besta
– sequence: 4
  givenname: Antonio Emanuele
  surname: Elia
  fullname: Elia, Antonio Emanuele
  organization: Unit of Neurology 1 - Parkinson and Movement Disorders, Fondazione IRCCS Istituto Neurologico Carlo Besta
– sequence: 5
  givenname: Roberto
  surname: Cilia
  fullname: Cilia, Roberto
  organization: Unit of Neurology 1 - Parkinson and Movement Disorders, Fondazione IRCCS Istituto Neurologico Carlo Besta
– sequence: 6
  givenname: Sara Maria
  surname: Portaleone
  fullname: Portaleone, Sara Maria
  organization: Department of Health Science, Santi Paolo e Carlo Hospital and Università degli Studi di Milano
– sequence: 7
  givenname: Wen
  surname: Wang
  fullname: Wang, Wen
  organization: Department of Pathology, Case Western Reserve University School of Medicine
– sequence: 8
  givenname: Irene
  surname: Tramacere
  fullname: Tramacere, Irene
  organization: Scientific Directorate, Fondazione IRCCS Istituto Neurologico Carlo Besta
– sequence: 9
  givenname: Edoardo
  surname: Bistaffa
  fullname: Bistaffa, Edoardo
  organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta
– sequence: 10
  givenname: Federico Angelo
  surname: Cazzaniga
  fullname: Cazzaniga, Federico Angelo
  organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta
– sequence: 11
  givenname: Giovanni
  surname: Felisati
  fullname: Felisati, Giovanni
  organization: Department of Health Science, Santi Paolo e Carlo Hospital and Università degli Studi di Milano
– sequence: 12
  givenname: Giuseppe
  surname: Legname
  fullname: Legname, Giuseppe
  organization: Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA)
– sequence: 13
  givenname: Alessio
  surname: Di Fonzo
  fullname: Di Fonzo, Alessio
  organization: Unit of Neurology, Foundation IRCCS Ca’ Granda Ospedale Maggiore
– sequence: 14
  givenname: Rong
  surname: Xu
  fullname: Xu, Rong
  organization: Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine
– sequence: 15
  givenname: Steven Alexander
  surname: Gunzler
  fullname: Gunzler, Steven Alexander
  organization: Department of Neurology, Case Western Reserve University School of Medicine, Department of Neurology, University Hospitals Cleveland Medical Center
– sequence: 16
  givenname: Giorgio
  surname: Giaccone
  fullname: Giaccone, Giorgio
  organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta
– sequence: 17
  givenname: Roberto
  surname: Eleopra
  fullname: Eleopra, Roberto
  organization: Unit of Neurology 1 - Parkinson and Movement Disorders, Fondazione IRCCS Istituto Neurologico Carlo Besta
– sequence: 18
  givenname: Shu Guang
  surname: Chen
  fullname: Chen, Shu Guang
  email: sxc59@case.edu
  organization: Department of Pathology, Case Western Reserve University School of Medicine, Department of Neurology, Case Western Reserve University School of Medicine
– sequence: 19
  givenname: Fabio
  orcidid: 0000-0002-2820-9880
  surname: Moda
  fullname: Moda, Fabio
  email: fabio.moda@istituto-besta.it
  organization: Unit of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34895275$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1DAUhiNURC_wAiyQJTZsUnxJ7IQF0mi4jVTErayt40umHiXx1E6owrvwrnhmStupUOVFnJPv_51z_B9nB73vbZY9J_iUkIq_joRhWuSYkhzjoib59Cg7IqLEOWGUH9zZH2bHMa4SJDAun2SHrKjqkoryKPvzzkUdXOd6GJzvkW_Q5x-z_CuC3mx3c6Qm9P08_zYu5qkI7RRd3GC-bUAPPkyoG7WP8AYNFxY1LsQBQYw2xs72w4ZMbzChYNfBm1E75Vo3TEjZ4craHg1XHsW11Q5a99sa1ILyAZKxs_Fp9riBNtpn18-T7OeH9-fzT_nZl4-L-ews11ywIRcUY14rBQZMI5QxpKqbmhPMVI0ZYEErBaXBnBWlZUbUaZWAK04UNLQu2Em22PkaDyu5TvOAMEkPTm4LPiwlhMHp1kpSEFsUjSFc6AJKCg0IrgTTQK0pAZLX253XelSdNToNIUC7Z7r_pXcXcul_yYrzklGRDF5dGwR_Odo4yC7dkW1b6K0fo6Qc1wXnoqoT-vIeuvJjSJe0oQhhJa8wvaWWkBpwfePTuXpjKme8ZiXjKUiJOv0PlZaxndMpeY1L9T3Bi7uN3nT4L1wJoDtABx9jsM0NQrDcJFjuEixTguU2wXJKouqeSLthm830O659WMp20pjO6Zc23E7jAdVf4ccGQQ
CitedBy_id crossref_primary_10_1016_j_parkreldis_2025_107772
crossref_primary_10_3233_JPD_240007
crossref_primary_10_1212_WNL_0000000000200878
crossref_primary_10_1002_alz_13859
crossref_primary_10_1109_JSEN_2023_3272659
crossref_primary_10_3390_ijms251910783
crossref_primary_10_1007_s12311_022_01471_8
crossref_primary_10_1093_jnen_nlac042
crossref_primary_10_3389_fnagi_2022_872629
crossref_primary_10_1080_14737159_2024_2403073
crossref_primary_10_1002_mds_29828
crossref_primary_10_1038_s41572_022_00382_6
crossref_primary_10_3389_fnagi_2022_1010064
crossref_primary_10_1002_mdc3_13710
crossref_primary_10_1016_j_mcpro_2023_100629
crossref_primary_10_1186_s40478_024_01873_1
crossref_primary_10_1001_jamaneurol_2024_3458
crossref_primary_10_1016_j_neubiorev_2024_105997
crossref_primary_10_1371_journal_ppat_1012554
crossref_primary_10_3390_biom13081263
crossref_primary_10_1038_s41531_024_00728_9
crossref_primary_10_1186_s40035_023_00345_1
crossref_primary_10_3390_brainsci12111579
crossref_primary_10_1007_s00018_022_04240_2
crossref_primary_10_1186_s40035_025_00469_6
crossref_primary_10_3390_cells11010087
crossref_primary_10_3389_fnmol_2022_975619
crossref_primary_10_1016_j_parkreldis_2022_10_007
crossref_primary_10_1016_j_exger_2024_112366
crossref_primary_10_1111_ene_16041
crossref_primary_10_3389_fneur_2023_1210220
crossref_primary_10_1038_s41591_023_02358_9
crossref_primary_10_1016_j_tibtech_2024_01_007
crossref_primary_10_1186_s40035_023_00370_0
crossref_primary_10_1007_s11010_024_05190_y
crossref_primary_10_1186_s40035_024_00449_2
crossref_primary_10_1186_s13578_023_01049_9
crossref_primary_10_1212_WNL_0000000000206881
crossref_primary_10_1038_s41531_023_00519_8
crossref_primary_10_1038_s41583_023_00697_7
Cites_doi 10.1016/S1474-4422(20)30269-6
10.1016/j.autneu.2017.11.002
10.1001/jamaneurol.2016.4547
10.1007/s00401-020-02160-8
10.1016/j.autneu.2017.10.007
10.1002/mds.23972
10.1002/mds.27646
10.1212/01.wnl.0000324625.00404.15
10.1073/pnas.1909322116
10.1186/s40035-019-0164-x
10.1038/s41598-020-65324-2
10.1111/nan.12311
10.1038/nrneurol.2012.80
10.1002/mds.26424
10.1002/acn3.338
10.1093/brain/awf080
10.1002/ana.25447
10.1038/s12276-019-0350-z
10.1136/jnnp-2017-315813
10.1111/j.1365-2990.2007.00907.x
10.1016/j.isci.2020.101166
10.1111/j.1749-6632.2009.04365.x
10.1111/j.1365-2990.2007.00874.x
10.1038/s41586-020-2317-6
10.1093/brain/awz189
10.1016/S1474-4422(12)70327-7
10.1186/s40478-018-0508-2
10.1074/jbc.RA118.004471
10.1002/mds.28242
10.1002/acn3.50897
10.1038/s41586-020-1984-7
10.1093/braincomms/fcab045
10.1007/s11481-019-09835-4
10.1002/mds.22340
ContentType Journal Article
Copyright The Author(s) 2021
2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13024-021-00491-y
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central (New)
ProQuest One
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
Publicly Available Content Database
MEDLINE


Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1750-1326
EndPage 19
ExternalDocumentID oai_doaj_org_article_141e44fd167c4a52afa76b73ca2ed5aa
PMC8665327
A693536130
34895275
10_1186_s13024_021_00491_y
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States--US
Italy
GeographicLocations_xml – name: United States--US
– name: Italy
GrantInformation_xml – fundername: Michael J. Fox Foundation, Alzheimer’s Association, Alzheimer’s Research UK and the Weston brain Institute
  grantid: BAND 11035
– fundername: US National Institutes of Health (NIH)/National Institute on Aging
  grantid: R01AG061388
– fundername: Ministero della Salute
  grantid: GR-2013-02355724 and Current Research
  funderid: http://dx.doi.org/10.13039/501100003196
– fundername: Associazione Italiana Encefalopatie da Prioni (AIEnP)
– fundername: American Parkinson Disease Association
  funderid: http://dx.doi.org/10.13039/100006309
– fundername: US National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke
  grantid: U01NS112010 and R01NS118760
– fundername: NINDS NIH HHS
  grantid: U01 NS112010
– fundername: NIA NIH HHS
  grantid: R01 AG061388
– fundername: NINDS NIH HHS
  grantid: R01 NS118760
– fundername: ;
  grantid: BAND 11035
– fundername: ;
– fundername: ;
  grantid: U01NS112010 and R01NS118760
– fundername: ;
  grantid: GR-2013-02355724 and Current Research
– fundername: ;
  grantid: R01AG061388
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
IPY
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
~8M
AAYXX
ALIPV
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7TK
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c673t-720069bbadadf7bdd189f96103b903a0728ba5d06345e3d797975a0861baf2943
IEDL.DBID M48
ISSN 1750-1326
IngestDate Wed Aug 27 01:06:35 EDT 2025
Thu Aug 21 18:20:22 EDT 2025
Fri Sep 05 04:47:14 EDT 2025
Fri Jul 25 03:32:07 EDT 2025
Tue Jun 17 21:30:36 EDT 2025
Tue Jun 10 20:29:40 EDT 2025
Mon Jul 21 05:59:54 EDT 2025
Tue Jul 01 01:59:05 EDT 2025
Thu Apr 24 23:08:35 EDT 2025
Sat Sep 06 07:29:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Real-Time Quaking-Induced Conversion
Biomarkers
Misfolding
Alpha-synuclein
Olfactory mucosa
Language English
License 2021. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c673t-720069bbadadf7bdd189f96103b903a0728ba5d06345e3d797975a0861baf2943
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2820-9880
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13024-021-00491-y
PMID 34895275
PQID 2611356802
PQPubID 55149
PageCount 19
ParticipantIDs doaj_primary_oai_doaj_org_article_141e44fd167c4a52afa76b73ca2ed5aa
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8665327
proquest_miscellaneous_2609466789
proquest_journals_2611356802
gale_infotracmisc_A693536130
gale_infotracacademiconefile_A693536130
pubmed_primary_34895275
crossref_primary_10_1186_s13024_021_00491_y
crossref_citationtrail_10_1186_s13024_021_00491_y
springer_journals_10_1186_s13024_021_00491_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-11
PublicationDateYYYYMMDD 2021-12-11
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-11
  day: 11
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Molecular neurodegeneration
PublicationTitleAbbrev Mol Neurodegeneration
PublicationTitleAlternate Mol Neurodegener
PublicationYear 2021
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References GM de Waal (491_CR24) 2020; 10
CH Hawkes (491_CR28) 2009; 1170
X Ding (491_CR29) 2020; 23
S Koga (491_CR4) 2018; 89
CG Goetz (491_CR22) 2008; 23
S Manne (491_CR17) 2020; 35
M Bongianni (491_CR34) 2019; 6
PG Glass (491_CR6) 2012; 27
RL Doty (491_CR5) 2012; 8
TR Yamasaki (491_CR10) 2019; 294
491_CR19
UJ Kang (491_CR20) 2019; 34
A van Rumund (491_CR33) 2019; 85
S Manne (491_CR14) 2019; 14
JQ Trojanowski (491_CR9) 2007; 33
BR Groveman (491_CR13) 2018; 6
CMG De Luca (491_CR16) 2019; 8
JA Palma (491_CR7) 2018; 211
M Shahnawaz (491_CR32) 2020; 578
S Gilman (491_CR1) 2008; 71
M Shahnawaz (491_CR15) 2017; 74
AJ Hughes (491_CR25) 2002; 125
CH Hawkes (491_CR27) 2007; 33
Z Wang (491_CR18) 2020; 78
H-J Lee (491_CR2) 2019; 51
E Valera (491_CR3) 2018; 211
Y Miki (491_CR11) 2019; 142
RB Postuma (491_CR21) 2015; 30
M Schweighauser (491_CR30) 2020; 585
GK Wenning (491_CR26) 2013; 12
M Rossi (491_CR31) 2020; 140
MG Spillantini (491_CR8) 2016; 42
A Pavel (491_CR35) 2020; 19
G Fairfoul (491_CR12) 2016; 3
MA Metrick (491_CR23) 2019; 116
References_xml – volume: 19
  start-page: 719
  issue: 9
  year: 2020
  ident: 491_CR35
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(20)30269-6
– volume: 211
  start-page: 1
  year: 2018
  ident: 491_CR3
  publication-title: Auton Neurosci
  doi: 10.1016/j.autneu.2017.11.002
– volume: 74
  start-page: 163
  issue: 2
  year: 2017
  ident: 491_CR15
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2016.4547
– volume: 140
  start-page: 49
  issue: 1
  year: 2020
  ident: 491_CR31
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-020-02160-8
– volume: 211
  start-page: 15
  year: 2018
  ident: 491_CR7
  publication-title: Auton Neurosci
  doi: 10.1016/j.autneu.2017.10.007
– volume: 27
  start-page: 327
  issue: 2
  year: 2012
  ident: 491_CR6
  publication-title: Mov Disord
  doi: 10.1002/mds.23972
– volume: 34
  start-page: 536
  issue: 4
  year: 2019
  ident: 491_CR20
  publication-title: Mov Disord
  doi: 10.1002/mds.27646
– volume: 71
  start-page: 670
  issue: 9
  year: 2008
  ident: 491_CR1
  publication-title: Neurology.
  doi: 10.1212/01.wnl.0000324625.00404.15
– volume: 116
  start-page: 23029
  issue: 46
  year: 2019
  ident: 491_CR23
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1909322116
– volume: 8
  start-page: 24
  issue: 1
  year: 2019
  ident: 491_CR16
  publication-title: Transl Neurodegener
  doi: 10.1186/s40035-019-0164-x
– volume: 10
  start-page: 8777
  issue: 1
  year: 2020
  ident: 491_CR24
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-65324-2
– volume: 42
  start-page: 3
  issue: 1
  year: 2016
  ident: 491_CR8
  publication-title: Neuropathol Appl Neurobiol
  doi: 10.1111/nan.12311
– volume: 8
  start-page: 329
  issue: 6
  year: 2012
  ident: 491_CR5
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2012.80
– volume: 30
  start-page: 1591
  issue: 12
  year: 2015
  ident: 491_CR21
  publication-title: Mov Disord
  doi: 10.1002/mds.26424
– volume: 3
  start-page: 812
  issue: 10
  year: 2016
  ident: 491_CR12
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.338
– volume: 125
  start-page: 861
  issue: Pt 4
  year: 2002
  ident: 491_CR25
  publication-title: Brain.
  doi: 10.1093/brain/awf080
– volume: 85
  start-page: 777
  issue: 5
  year: 2019
  ident: 491_CR33
  publication-title: Ann Neurol
  doi: 10.1002/ana.25447
– volume: 51
  start-page: 1
  issue: 11
  year: 2019
  ident: 491_CR2
  publication-title: Exp Mol Med
  doi: 10.1038/s12276-019-0350-z
– volume: 89
  start-page: 175
  issue: 2
  year: 2018
  ident: 491_CR4
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2017-315813
– volume: 33
  start-page: 615
  issue: 6
  year: 2007
  ident: 491_CR9
  publication-title: Neuropathol Appl Neurobiol
  doi: 10.1111/j.1365-2990.2007.00907.x
– volume: 23
  start-page: 101166
  issue: 6
  year: 2020
  ident: 491_CR29
  publication-title: iScience
  doi: 10.1016/j.isci.2020.101166
– volume: 1170
  start-page: 615
  issue: 1
  year: 2009
  ident: 491_CR28
  publication-title: Ann N Y Acad Sci
  doi: 10.1111/j.1749-6632.2009.04365.x
– volume: 33
  start-page: 599
  issue: 6
  year: 2007
  ident: 491_CR27
  publication-title: Neuropathol Appl Neurobiol
  doi: 10.1111/j.1365-2990.2007.00874.x
– volume: 585
  start-page: 464
  issue: 7825
  year: 2020
  ident: 491_CR30
  publication-title: Nature.
  doi: 10.1038/s41586-020-2317-6
– volume: 142
  start-page: 2813
  issue: 9
  year: 2019
  ident: 491_CR11
  publication-title: Brain.
  doi: 10.1093/brain/awz189
– volume: 78
  start-page: 1
  issue: 1
  year: 2020
  ident: 491_CR18
  publication-title: JAMA Neurol
– volume: 12
  start-page: 264
  issue: 3
  year: 2013
  ident: 491_CR26
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(12)70327-7
– volume: 6
  start-page: 7
  issue: 1
  year: 2018
  ident: 491_CR13
  publication-title: Acta Neuropathol Commun
  doi: 10.1186/s40478-018-0508-2
– volume: 294
  start-page: 1045
  issue: 3
  year: 2019
  ident: 491_CR10
  publication-title: J Biol Chem
  doi: 10.1074/jbc.RA118.004471
– volume: 35
  start-page: 2230
  issue: 12
  year: 2020
  ident: 491_CR17
  publication-title: Mov Disord
  doi: 10.1002/mds.28242
– volume: 6
  start-page: 2120
  issue: 10
  year: 2019
  ident: 491_CR34
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.50897
– volume: 578
  start-page: 273
  issue: 7794
  year: 2020
  ident: 491_CR32
  publication-title: Nature.
  doi: 10.1038/s41586-020-1984-7
– ident: 491_CR19
  doi: 10.1093/braincomms/fcab045
– volume: 14
  start-page: 423
  issue: 3
  year: 2019
  ident: 491_CR14
  publication-title: J NeuroImmune Pharmacol
  doi: 10.1007/s11481-019-09835-4
– volume: 23
  start-page: 2129
  issue: 15
  year: 2008
  ident: 491_CR22
  publication-title: Mov Disord
  doi: 10.1002/mds.22340
SSID ssj0047005
Score 2.4821842
Snippet Background Detection of the pathological and disease-associated alpha-synuclein (αSyn D ) in the brain is required to formulate the definitive diagnosis of...
Detection of the pathological and disease-associated alpha-synuclein (αSyn ) in the brain is required to formulate the definitive diagnosis of multiple system...
Background Detection of the pathological and disease-associated alpha-synuclein ([alpha]Syn.sup.D) in the brain is required to formulate the definitive...
Detection of the pathological and disease-associated alpha-synuclein ([alpha]Syn.sup.D) in the brain is required to formulate the definitive diagnosis of...
Background Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of...
Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis of multiple system...
Abstract Background Detection of the pathological and disease-associated alpha-synuclein (αSynD) in the brain is required to formulate the definitive diagnosis...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 82
SubjectTerms Age
Alpha-synuclein
Alzheimer's disease
Antibodies
Atrophy
Basal ganglia
Biomarkers
Biomedical and Life Sciences
Biomedicine
Central nervous system diseases
Cerebellum
Clinical trials
COVID-19
Diagnosis
Drug therapy
Ethics
Humans
Laboratories
Magnetic resonance imaging
Misfolding
Molecular Medicine
Movement disorders
Mucosa
Multiple System Atrophy - pathology
Neurodegenerative diseases
Neurology
Neuromuscular diseases
Neurosciences
Olfactory discrimination
Olfactory discrimination learning
Olfactory epithelium
Olfactory mucosa
Olfactory Mucosa - chemistry
Olfactory Mucosa - pathology
Parkinson Disease - diagnosis
Parkinson Disease - pathology
Parkinson's disease
Patients
Phenotypes
Real-Time Quaking-Induced Conversion
Reproducibility
Reproducibility of Results
Research Article
Seeding
Synuclein
Tomography
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQUB6BgoyE4ABW49iObW7LQlWQini0Um-WndhipTZB7K5Q-C_8Vzx2dmmKgAvaSzaeSLbn83jGmXyD0GPGfHQKykAaXTrCndREWR5DFdo0wjWybCycQx69qw9P-NtTcXqh1BfkhGV64Dxx-5RTz3loaS0bbkVlg5W1k6yxlW-FTa5RqctNMJVtMJcRXJtPZFS9v4TXc5xAOgK4xJQMk20osfX_bpMvbEqXEyYvvTVNm9HBdXRt9CLxLPf-Brriu5tod9bFCPp8wE9wyutMB-a76MerBZgGSHkBJeA-4KNPM_Ie265NV3PsBvzxmHxYv5nHm5mkBMT6s1yNZ8DnkNduX-DoLeKwiA4jtltGT5CM_-yAgSAT-GNzwu2AxxwwvPrW42Wuc7_47ls8Aq-HKP0WOjl4fTw_JGNRBtLUkq2IhDMI7ZxtbRuka1uqdNDRCWNOl8yWslLOijZ6Plx41kodf8LGwIk6GyrN2W200_Wdv4swOHu-8papCA_nrbalUIFTx0LwoVUFohsdmWZkLIfCGWcmRS6qNlmvJurVJL2aoUDPts98yXwdf5V-CarfSgLXdroREWhGBJp_IbBATwE4BixC7F5jxw8b4iCBW8vMas0EgzitQHsTybiSm2nzBnpmtCRLEyNcykStyqpAj7bN8CRkx3W-X4NMCWUCpNIFupORuh0S40qLSooCyQmGJ2OetnSLz4lnHKgQWSUL9HyD9l_d-vOc3vsfc3ofXa1gtdKKULqHdlZf1_5B9P5W7mFa6D8BkQ1YWQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXLggoDwCBRkJwQGsxrEdx1zQslAVpCIerbS3yE9YqU1Kd1co_Bf-K568Soqo9rIbT6R4Zzz-Zjz5BqGnjPkICtJArEoN4UYqUmgeQxVqrTBWplZDHvLgY75_xD8sxKJPuK36ssrBJ7aO2tUWcuS7EelTJvIizV6f_iDQNQpOV_sWGlfRNRqRCLRukIsx4OIymtjwokyR767gkI4TKEoAYExJM9mMWs7-fz3zX1vTxbLJC2en7Za0dxPd6LEknnXKv4Wu-Oo22p5VMY4-afAz3FZ3tmnzbfT77RIcBBS-gCpwHfDB1xn5hHXl2m9zbBr85ZB83ryfx4sdVQmI1cddT54Gn0B1u36FI2bEYRlhI9YjrydIxl-6wUCTCSyyXdltg_tKMLz-WeNV1-1--cs73JtfDbH6HXS09-5wvk_61gzE5pKtiYRMhDJGO-2CNM7RQgUVoRgzKmU6lVlhtHAR_3DhmZMqfoSO4RM1OmSKs7toq6orfx9hgHw-85oV0UiM10qnogicGhaCD65IEB10VNqetxzaZxyXbfxS5GWn1zLqtWz1WjYJejHec9qxdlwq_QZUP0oC43Z7oT77VvYLOIZI1HMeHM2l5VpkOmiZG8mszrwTWifoORhOCX4hPp7V_esNcZLAsFXOcsUEg2gtQTsTybie7XR4ML2y9yer8tz6E_RkHIY7oUau8vUGZFJoFiALlaB7naWOU2K8UCKTIkFyYsOTOU9HquX3lm0cCBFZJhP0crD288f6_3_64PJZPETXM1iHNCOU7qCt9dnGP4robm0et0v4D5BrTq0
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagXLggoDwCBRkJwQEs4tiObW7LQlWQini0Um-Wn-pKbYLorlD4L_xXPEl2acpDQnvJ2mMpzny2Z-zxNwg9Zixmo6BMxOvSEe6kJsry7KpQ74XzsvQW9iH339d7h_zdkTgaaXLgLsz583uq6hdncLDGCQQSgDFLSXcZXRG5ENA8r-frWZfLDKf1pZg_tpssPD0__--z8Lll6GKI5IVz0n752b2Oro12I54Nir6BLsXmJtqeNdlnPu3wE9xHcvZb5Nvox-sFTAYQ5AKfHbcJ73-ekQ_YNqF_mmPX4U8H5OPq7TwXDrQkINaeDPl3OnwKkez2Jc72IU6LbCJiu-HwBMn8z3YYKDGBMXYIse3wGPWFl99afDZktl98jwGPUGvBL7-FDnffHMz3yJiGgfhasiWRsOugnbPBhiRdCFTppLPZxZwumS1lpZwVIds6XEQWpM4_YbOrRJ1NlebsNtpq2ibeRRjMu1hFy1QGhItW21KoxKljKcUUVIHoWkfGjxzlkCrjxPS-iqrNoFeT9Wp6vZquQM82bb4MDB3_lH4Fqt9IArt2X5BBZ8bBmt0hGjlPgdbScysqm6ysnWTeVjEIawv0FIBjYA7Ir-fteJUhdxLYtMys1kww8MwKtDORzGPXT6vX0DPj3HFmsk9LmahVWRXo0aYaWkI8XBPbFciUkBhAKl2gOwNSN11iXGlRSVEgOcHwpM_TmmZx3DOLA_khq2SBnq_R_uu1_v5N7_2f-H10tYJxSStC6Q7aWn5dxQfZslu6h_2Q_gknakgI
  priority: 102
  providerName: Springer Nature
Title Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories
URI https://link.springer.com/article/10.1186/s13024-021-00491-y
https://www.ncbi.nlm.nih.gov/pubmed/34895275
https://www.proquest.com/docview/2611356802
https://www.proquest.com/docview/2609466789
https://pubmed.ncbi.nlm.nih.gov/PMC8665327
https://doaj.org/article/141e44fd167c4a52afa76b73ca2ed5aa
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELb6uHBBQHkEyspICA4QSGInTpAQSpdWZaVWpe1KvUV2YpeVtglsdwXhv_BfmXEekFIQyiGJPYnszEw8Y4-_IeQpYxqMAs-4eeIplyuRuLHk4Kr4eR6qXHi5xHnIg8Nof8onZ-HZGunSHbUf8PJa1w7zSU0X81ffvtTvQOHfWoWPo9eXuPjGXQw2QIPXd-t1smnXizCUj_erClx4NqQRRkzPBS8s6jbRXPuOwUBl8fz__Gv_NmxdDam8sq5qh6u9W-Rma2fStBGM22RNl3fIVlqCj31R02fURn7aKfUt8uP9DH8eGBSDbKKVoQcnqXtEZVnYqzFVNT0-dT-uPoyhsIExQbJq3uTrqekFRr7LNxTsSWpmYFJS2WN-IiXcyZoihCYizDYhuTVto8To8mtFcc8nKMPsuy5oK5oV-vF3yXRv93S877ZpG9w8EmzpCpylSJSShSyMUEXhx4lJwExjKvGY9EQQKxkWYBvxULNCJHCEElwrX0kTJJzdIxtlVeoHhKI5qAMtWQwCpLRMpBfGhvuKGaNNETvE73iU5S2mOabWmGfWt4mjrOFrBnzNLF-z2iEv-mc-N4ge_6TeQdb3lIjGbQuqxXnWKje4T77m3BR-JHIuw0AaKSIlWC4DXYRSOuQ5Ck6GUgzNy2W79QE6iehbWRolLGToyTlke0AJup4PqzvRyzpVycAH9lkYxV7gkCd9NT6J8XOlrlZI42EiAREnDrnfSGrfJcbjJAxE6BAxkOFBn4c15eyTRSJHsEQWCIe87KT9V7P-_k0f_kczH5EbASqjH7i-v002louVfgzm31KNyLo4EyOymaaTkwmcd3YPj46hdByNR3ZKZWS1_ifSF1vu
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZG9wAvCBiwwAAjcXkAa0nsxDHShLpuU8fWaoxO2lvwLVBpS8baagr_hb_Cb8Mnl44OsbepL218EsU9x-fm4-8g9IpS65wCPyNa-IowxQVJJHOhSqB1pDT3tYQ85GAY94_Yp-PoeAn9bs_CQFllqxMrRW0KDTnydefpBzSKEz_8ePaDQNco2F1tW2jIprWC2aggxpqDHXu2vHAh3GRjd8vx-3UY7myPen3SdBkgOuZ0SjgE1UIpaaTJuDImSEQmnFdBlfCp9HmYKBkZZ8pZZKnhwn0i6SKBQMksFIy6595CywwSKB20vLk9PDhsbQHjTsjbozpJvD6BbUJGoCwCXPOAlAvmsOoa8K9t-Ms4Xi3cvLJ7WxnFnXvobuPN4m4tfvfRks0foJVu7iL50xK_wVV9aZW4X0G_tsagoqD0BoQBFxkefOmSAyxzU33rYVXiwxH5PNvtuYs1WAqQFSd1V6ASn0J9vfyAndeKs7FzXLGcI4sCpfslSwxAnYBjWxf-lripRcPTiwLDyVK35MY_rcHNAiggW_AQHd0I2x6hTl7kdhVhcDptaCVNnJgqK4X0oyRjgaJZZjOTeChoeZTqBjkdGnicpFUElcRpzdfU8TWt-JqWHno3v-esxg25lnoTWD-nBMzv6kJx_i1tVIgL0gLLWGaCmGsmo1BmkseKUy1DayIpPfQWBCcFzeReT8vmgIWbJGB8pd1Y0IhCvOihtQVKp1H04nAremmj0Sbp5frz0Mv5MNwJVXq5LWZA40O7Ap4IDz2uJXU-JcoSEYU88hBfkOGFOS-O5OPvFd45QDLSkHvofSvtl6_1___0yfWzeIFu90eD_XR_d7j3FN0JYU0GIQmCNdSZns_sM-drTtXzZkFj9PWmdcgff3mROQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaglRAXBJRHoICREBwgahzbsc0tbFm1C60KbaXeLDuxYaU2qbq7QuG_8F_x5LF0y0NCuSTxWIozD8_Y428QekGpC05B4uNCJTZmVqhYGhZCFVIU3BYiKQysQ-7tZzvHbHLCTy6d4m-z3Yctye5MA6A0VfOt89J3Ki6zrRlst7EY0gvAxSVxcx2tS65UCL_W83xyOBmsMRNBzIbDMn_suTIhtbj9v1vnS9PT1dTJK_un7bQ0vo1u9f4kzjsBuIOuueou2sirEEufNfglbjM826XzDfRjewpGApJfgB249njvMI8PsKnK9m6EbYM_H8WfFruj8LKDKwGy-rSry9PgM8hwN29x8BuxnwbXEZsltidQhifTYIDKBCTZLvW2wX02GJ5_q_Gsq3g__e5K3ItgDfH6PXQ8fn802on78gxxkQk6jwWsRihrTWlKL2xZEqm8Cu4YtSqhJhGptIaXwQdi3NFSqHBxE0IoYo1PFaP30VpVV-4hwuD2udQZKoOgWGeUSbj0jFjqvfOljBAZeKSLHrscSmic6jaGkZnu-KoDX3XLV91E6PWyz3mH3PFP6nfA-iUloG63L-qLL7pX4hAmEceYL0kmCmZ4arwRmRW0MKkruTERegWCo8E2hM8rTH_EIQwSULZ0ninKKURsEdpcoQw6Xaw2D6Kne5sy0yHWJZRnMkkj9HzZDD0hT65y9QJoEigYIKSK0INOUpdDokwqngoeIbEiwytjXm2ppl9bxHEARaSpiNCbQdp_fdbf_-mj_yN_hm4cbI_1x939D4_RzRRUlKQxIZtobX6xcE-C8ze3T3v9_gkjjlS1
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discrimination+of+MSA-P+and+MSA-C+by+RT-QuIC+analysis+of+olfactory+mucosa%3A+the+first+assessment+of+assay+reproducibility+between+two+specialized+laboratories&rft.jtitle=Molecular+neurodegeneration&rft.au=Bargar%2C+Connor&rft.au=De+Luca%2C+Chiara+Maria+Giulia&rft.au=Devigili%2C+Grazia&rft.au=Elia%2C+Antonio+Emanuele&rft.date=2021-12-11&rft.issn=1750-1326&rft.eissn=1750-1326&rft.volume=16&rft.issue=1&rft.spage=82&rft_id=info:doi/10.1186%2Fs13024-021-00491-y&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1326&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1326&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1326&client=summon